The present study examined the effects of the impairment of corticostriatal and nigrostriatal dopaminergic transmission on the mean number and the topographical distribution of somatostatin-containing neurons in frontal sections of the rat rostral striatum. These neurons, visualized by an immunohistochemical method using a specific anti-somatostatin(28) antibody were shown to be unevenly distributed; the number of immunoreactive perikarya being consistently lower in the dorsolateral and higher in the middle areas of striatal sections than in the remaining parts of the structure. Such a distribution and number were not altered either by unilateral 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal dopaminergic neurons after 2- to 3-week survival periods, or by alpha-methylparatyrosine-induced dopamine depletion. In animals with similar 6-OHDA-induced lesions, no change in the striatal concentration of somatostatin measured by radioimmunoassay was observed. These results suggest that somatostatin levels in striatal neurons are not under a dopaminergic influence in contrast to that previously described for neuropeptide Y, although both peptides are thought to coexist extensively in the same striatal neuron population. On the contrary, extensive unilateral frontoparietal ablation of the cerebral cortex elicited, 2-3 weeks later, a significant increase in the mean number of somatostatin-immunoreactive cells per section in the ipsilateral striatum preferentially localized to the dorsolateral zone of the structure with no change in the contralateral side. Data from immunohistochemical studies were further discussed in comparison with results obtained by radioimmunoassay showing that similar cortical lesion induced no change in somatostatin endogenous levels in the ipsilateral striatum and a 30% decreased concentration of the peptide in the contralateral striatum. These data suggest that the corticostriatal pathway influences the expression of somatostatin at either a translational, processing or metabolic level in a topographically restricted population of striatal somatostatin-containing neurons.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0006-8993(90)91520-qDOI Listing

Publication Analysis

Top Keywords

nigrostriatal dopaminergic
12
corticostriatal nigrostriatal
8
somatostatin-containing neurons
8
ipsilateral striatum
8
striatum
5
neurons
5
striatal
5
somatostatin-immunoreactive neurons
4
neurons rat
4
rat striatum
4

Similar Publications

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder characterized by the progressive loss of nigrostriatal dopaminergic neurons (DA) which can be caused by environmental and genetic factors. lncRNAs have emerged as an important regulatory layer in neurodegenerative disorders, including PD. In this study, we investigated and validated lncRNAs that may serve as diagnostic or therapeutic targets for PD.

View Article and Find Full Text PDF

Autism spectrum disorder (ASD) is a complex developmental disorder characterized by several behavioral impairments, especially in socialization, communication, and the occurrence of stereotyped behaviors. In rats, prenatal exposure to valproic acid (VPA) induces autistic-like behaviors. Previous studies by our group have suggested that the autistic-like phenotype is possibly related to dopaminergic system modulation because tyrosine hydroxylase (TH) expression was affected.

View Article and Find Full Text PDF

Peripherally administered TNF inhibitor is not protective against α-synuclein-induced dopaminergic neuronal death in rats.

Neurobiol Dis

January 2025

Department of Biomedicine & Danish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, 8000 Aarhus, Denmark. Electronic address:

The underlying cause of neuronal loss in Parkinson's disease (PD) remains unknown, but evidence implicates neuroinflammation in PD pathobiology. The pro-inflammatory cytokine soluble tumor necrosis factor (TNF) seems to play an important role and thus has been proposed as a therapeutic target for modulation of the neuroinflammatory processes in PD. In this regard, dominant-negative TNF (DN-TNF) agents are promising antagonists that selectively inhibit soluble TNF signaling, while preserving the beneficial effects of transmembrane TNF.

View Article and Find Full Text PDF

Parkinson's disease (PD) is the most prominent and highly prevalent chronic neuro-degenerative disease generally recognized by classical motor symptoms which are linked with genetic mutation, Lewy bodies, and subsequently selective loss of nigrostriatal dopaminergic neurons. The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier protect the central nervous system against toxins and are the most significant barriers to effective brain drug delivery in managing Parkinsonism. In recent years, intranasal delivery has attracted remarkable attention for brain targeting as the drug can be administered to the brain directly from the nose employing the trigeminal and olfactory pathways.

View Article and Find Full Text PDF

Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Brain Sci

November 2024

Department of Public Safety and Correctional Services, Baltimore, MD 21215, USA.

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. It is defined by motor and nonmotor symptoms including a spectrum of cognitive impairments known as Parkinson's disease dementia (PDD). Currently, the only US Food and Drug Administration-approved treatment for PDD is rivastigmine, which inhibits acetylcholinesterase and butyrylcholinesterase increasing the level of acetylcholine in the brain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!